Companies in #Genomics
Found 3 companies operating in this sector.
10x Genomics, Inc. develops and sells instruments, consumables and software for analysing biological systems at single-cell and spatial resolution. Its Chromium platform profiles individual cells for single-cell gene expression and methylation, its Visium platform maps the physical location of analytes within tissue sections, and its Xenium platform images hundreds of RNA targets directly in tissue without conventional sequencing. The supporting software suite includes Cell Ranger, Loupe Browser and Xenium Explorer. Customers span academic and government research institutions, biopharmaceutical and biotechnology companies and other organisations studying oncology, immunology and neuroscience. The company was founded in 2012 and is headquartered in Pleasanton, California.
Illumina (NASDAQ: ILMN) is the dominant maker of DNA sequencing machines and integrated genomics platforms, with installed instruments across academic, clinical, and pharmaceutical research worldwide. The San Diego-based company sells the NovaSeq X, NextSeq, and MiSeq lines of sequencing systems, the TruSight and AmpliSeq targeted-resequencing portfolios, and the DRAGEN secondary-analysis software. Illumina is also pushing into clinical sequencing through its Illumina Connected Software and the TruSight Oncology Comprehensive genomic profiling assay, and spun off its GRAIL liquid-biopsy subsidiary in 2024.
Twist Bioscience Corporation is a synthetic biology company that manufactures synthetic DNA at scale on a proprietary silicon-based synthesis platform. Its product lines include synthetic genes, oligo pools, variant libraries, antibody discovery libraries, next-generation sequencing target enrichment panels and biopharma drug-discovery services, sold into healthcare, industrial chemicals, agriculture and academic research markets. The company was founded in 2013 and is headquartered in South San Francisco, California. Its discovery-data offering supplies machine-learning-ready small-molecule and antibody developability data to pharmaceutical partners, including an October 2026 agreement with Eli Lilly's TuneLab network.